Using mice models to gain insight into immune response to SARS-CoV-2

By Jane Byrne contact

- Last updated on GMT

© GettyImages/reklamlar
© GettyImages/reklamlar

Related tags: SARS-COV-2, Dengue, Zika, Immune system

Charles River and La Jolla Institute for Immunology (LJI) are collaborating on a new project to uncover how different cells in the human immune system respond to SARS-CoV-2 in early, acute infection.

Their new research alliance is aimed at enabling scientists to better understand how the body responds to the virus, from day one of infection. 

Dr Sujan Shresta (on the left) and Dr Kenneth Kim will investigate how susceptible ACEihumanized mice are to SARS-CoV-2 infection © Charles River

The work at LJI, led by Professor Sujan Shresta, will provide the first in-depth characterization of an ACE2ihumanized mouse model of SARS-CoV-2 infection, made available by Charles River through a licensing deal it secured with Gempharmatech, LTD.

This new mouse model has been engineered to express human ACE2, the receptor that SARS-CoV-2 uses to infect human cells, and includes the same immune cells made by the human body, allowing for a close look at human immune responses, said Charles River.

“This brand new mouse model is a tremendous opportunity for my lab to study the human immune response on a timescale which is just not possible with clinical studies,” ​commented Shresta.

Her lab will be working closely with Kenneth Kim, director of the LJI Histopathology Core, on the project.

Currently, with human patients, researchers can only look at the immune response after there have been signs of infection. With this new mouse model, researchers will be able to understand better mechanisms of early infection in an immuno-humanized mouse and have a critical window into the human immune response that cannot be obtained in clinical studies, explained the CRO.

Immune response to infectious diseases

Shresta is an expert in using mouse models to study immune responses to infectious diseases, noted Charles River. Her laboratory has led research into virus-host interactions in diseases such as dengue, Zika and Japanese encephalitis. This work has shed light on the precise balance of immune cell types needed to fight off these potentially deadly viruses, noted the CRO.

The professor is also a member of the LJI Coronavirus Task Force and has worked to establish COVID-19 research partnerships in Nepal, Vietnam and the Philippines. 

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more